(87 days)
Not Found
No
The description focuses on the hardware and basic electronic functionality of a multi-programmable electrical stimulator for pain management. There is no mention of AI, ML, or any advanced algorithms for data analysis, pattern recognition, or adaptive stimulation based on patient feedback or physiological data.
Yes
The device is indicated for the treatment of chronic pain, which is a therapeutic purpose.
No
The device is indicated for the treatment of chronic pain and for trial stimulation to deliver targeted paresthesia, not for diagnosing a condition.
No
The device description explicitly states the system consists of an "external stimulator," "trial cables," and "percutaneous trial lead," which are all hardware components. The software is part of a larger hardware system designed to deliver electrical impulses.
Based on the provided text, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use clearly states the device is for the "treatment of chronic pain of the trunk and limbs" by delivering electrical impulses to nerve structures. This is a therapeutic use, not a diagnostic one.
- Device Description: The description details an external stimulator, cables, and implanted leads designed to deliver electrical pulses. This aligns with a therapeutic device for nerve stimulation.
- Lack of IVD Characteristics: There is no mention of the device being used to examine specimens derived from the human body (like blood, urine, tissue, etc.) to provide information for diagnosis, monitoring, or compatibility testing.
Therefore, the Multiprogram Trial Stimulator System is a therapeutic device, not an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
The Multiprogram Trial Stimulator System is indicated for the treatment of chronic pain of the trunk and limbs, either as the sole mitigating agent or as an adjunct to other modes of therapy used in a multidisciplinary approach.
The Multiprogram Trial Stimulator System is intended to be used with St. Jude Medical Neuromodulation Division percutaneous trial leads and external test extensions to deliver targeted paresthesia to single or multiple painful sites for trial stimulation either intraoperatively or postoperatively for up to a maximum of 30 days.
The St. Jude Medical Neuromodulation Division neurostimulation systems are indicated for spinal cord stimulation (SCS) in the treatment of chronic pain of the trunk and limbs, either as the sole mitigating agent, or as an adjunct to other modes of therapy used in a multidisciplinary approach.
St. Jude Medical Neuromodulation Division percutaneous leads model numbers 3066, 3161, 3163, 3166, 3169, extension model numbers 3382, 3383, 3341, 3342, 3343, and receiver model number 3408, transmitter model number 3508, and antenna model numbers 1220 and 1230 are also indicated to stimulate electrically peripheral nerves to relieve severe intractable pain.
Product codes
GZB, GZF
Device Description
The MTS™ System (also called the Multiprogram Trial Stimulator) is a multi-programmable device designed to deliver low intensity electrical impulses to nerve structures in the dorsal aspect of the spinal cord. The system consists of an external stimulator, one or two trial cables, and a single or multiple percutaneous trial lead. The trial stimulator is a battery-powered device that can be worn by the patient and is intended to deliver targeted paresthesia to single or multiple painful stimulation either intraoperatively or post operatively for a maximum of 30 days. The device contains electronic circuitry that combines the function of a receiver and a transmitter and allows the stimulator to be easily programmed to deliver electrical pulses via sixteen output polarities through the trial cable to the implanted lead. The Trial Stimulator communicates via an RS232 port with the Rapid Programmer.
The wide-spaced Quattrode trial and permanent leads are for use in spinal cord stimulation and peripheral nerve stimulation. Each lead consists of a variety of platinum iridium electrodes on the distal end connected by individually insulated wires to platinum iridium contact bands on the proximal end. The insulated wires are covered by a biocompatible polyurethane or silicone rubber sheath. The lead assembly consists of 4 cylindrical electrodes spaced at precise intervals. These leads are designed for introduction into the epidural space using an epidural needle, a guide wire, the optional Introde-AK (Introde) lead introducer, and a stylet to aid in positioning. Also, the permanent wide-spaced Quattrode leads (model #s: 3161, 3163, 3166 and 3169) are designed to be placed directly on or adjacent to a peripheral nerve. The exception is found with the wide-spaced Quattrode trial leads (model #3066) in that they are used during a trial implantation period not to exceed 30 days.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Spinal cord, Peripheral nerves
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
A clinical evaluation was performed on the MTS™ System which includes associated accessory devices such as leads. This evaluation provides evidence to support the replacement of the contraindication for demand-type cardiac pacemakers with a warning that provides the clinician with mitigators to reduce the risk of spinal cord stimulation (SCS) interference with cardiac device functionality in patients with concomitant systems. The evidence to support this change includes prospective clinical evidence, a systematic literature review, and complaint data analysis.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
MTS™ Multiprogram Trial Stimulator System (K033757), Wide-Spaced Quattrode™ Leads (K072462)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 882.5880 Implanted spinal cord stimulator for pain relief.
(a)
Identification. An implanted spinal cord stimulator for pain relief is a device that is used to stimulate electrically a patient's spinal cord to relieve severe intractable pain. The stimulator consists of an implanted receiver with electrodes that are placed on the patient's spinal cord and an external transmitter for transmitting the stimulating pulses across the patient's skin to the implanted receiver.(b)
Classification. Class II (performance standards).
0
JAN 1 8 2013
St. JUDE MEDICAL
MORE CONTROL. LESS RISK
St. Jude Medical Neuromodulation Division 1 Preston Road
510(k) Summary Contact Information Owner/Operator: St. Jude Medical, Inc., Neuromodulation Division Terrina Wilder, RAC Submitter's Name: 6901 Preston Rd., Plano, TX 75024 Address: (972) 309-8115 (Office) (972) 309-8265 (Fax) Telephone Number: October 19, 2012 Date:
Device Names
6.0
Trade Names:
Common or Usual Names:
Classification:
Classification Names:
Class II
CFR 882.5870)
MTS™ System
MTS™ System
Stimulator, Spinal Cord, Implanted for Pain Relief (21 CFR 882.5880) Stimulator, Peripheral Nerve, Implanted for Pain Relief (21
Wide-Spaced Quattrode™ Percutaneous Lead Wide-Spaced Quattrode™ Percutaneous Trial Lead
Wide-Spaced Quattrode™ Percutaneous Lead Wide-Spaced Quattrode™ Percutaneous Trial Lead
Predicate Device Names :
MTS™ Multiprogram Trial Stimulator System (K033757) Wide-Spaced Quattrode™ Leads (K072462)
Establishment Registration Number: 1627487
Device Description
MTS™ System
The MTS™ System (also called the Multiprogram Trial Stimulator) is a multi-programmable device designed to deliver low intensity electrical impulses to nerve structures in the dorsal aspect of the
Page 12 of 30
1
spinal cord. The system consists of an external stimulator, one or two trial cables, and a single or multiple percutaneous trial lead.
The trial stimulator is a battery-powered device that can be worn by the patient and is intended to deliver targeted paresthesia to single or multiple painful stimulation either intraoperatively or post operatively for a maximum of 30 days. The device contains electronic circuitry that combines the function of a receiver and a transmitter and allows the stimulator to be easily programmed to deliver electrical pulses via sixteen output polarities through the trial cable to the implanted lead. The Trial Stimulator communicates via an RS232 port with the Rapid Programmer.
Wide-Spaced Quattrode™ Trial and Permanent Leads
The wide-spaced Quattrode trial and permanent leads are for use in spinal cord stimulation and perioheral nerve stimulation. Each lead consists of a variety of platinum iridium electrodes on the distal end connected by individually insulated wires to platinum iridium contact bands on the proximal end. The insulated wires are covered by a biocompatible polyurethane or silicone rubber sheath. The lead assembly consists of 4 cylindrical electrodes spaced at precise intervals. These leads are designed for introduction into the epidural space using an epidural needle, a guide wire, the optional Introde-AK (Introde) lead introducer, and a stylet to aid in positioning. Also, the permanent wide-spaced Quattrode leads (model #s: 3161, 3163, 3166 and 3169) are designed to be placed directly on or adjacent to a peripheral nerve. The exception is found with the widespaced Quattrode trial leads (model #3066) in that they are used during a trial implantation period not to exceed 30 days.
Indications for Use Statements
MTS™ System
The Multiprogram Trial Stimulator System is indicated for the treatment of chronic pain of the trunk and limbs, either as the sole mitigating agent or as an adjunct to other modes of therapy used in a multidisciplinary approach.
The Multiprogram Trial Stimulator is intended to be used with St. Jude Medical Neuromodulation Division percutaneous trial leads and external test extensions to deliver paresthesia to single or multiple painful sites for trial stimulation either intraoperatively or postoperatively for up to a maximum of 30 days.
Wide-Spaced Quattrode™ Percutaneous Leads
The St. Jude Medical Neuromodulation Division neurostimulation systems are indicated for spinal cord stimulation (SCS) in the treatment of chronic pain of the trunk and limbs, either as the sole mitigating agent, or as an adjunct to other modes of therapy used in a multidisciplinary approach.
St. Jude Medical Neuromodulation Division percutaneous leads model number 3066, 3163, 3166, 3169, extension model numbers 3382, 3383, 3341, 3342, 3343, and receiver model number 3408, transmitter model number 3508, and antenna model numbers 1220 and 1230 are also indicated to stimulate electrically peripheral nerves to relieve severe intractable pain.
The intended uses for the MTS™ System and the Wide-Spaced Quattrode™ Percutaneous Leads are the same as the predicate devices. The proposed change to replace the demand-type pacemaker. contraindication does not affect the safe and effective use of the medical devices.
Technological Characteristics
Summary of Non-clinical Studies
2
Non-clinical data performed to support previous submissions would still be applicable and would support this submission as well. As an effort to evaluate the continued safety and effectiveness of the medical devices mentioned in this submission, a risk evaluation was conducted. Identified risks were mitigated by replacing the contraindication for demand-type pacemakers with a warning statement instructing clinicians to verify that there is no interference between the implantable devices intraoperatively and to avoid a unipolar programming mode.
Summary of Clinical Studies
A clinical evaluation was performed on the MTS™ System which includes associated accessory devices such as leads. This evaluation provides evidence to support the replacement of the contraindication for demand-type cardiac pacemakers with a warning that provides the clinician with mitigators to reduce the risk of spinal cord stimulation (SCS) interference with cardiac device functionality in patients with concomitant systems. The evidence to support this change includes prospective clinical evidence, a systematic literature review, and complaint data analysis.
Conclusion
As a result of the non-clinical and clinical data demonstrated that the MTS™ System and the Wide-Spaced Quattrode™ Leads are as safe, effective and perform as well as the legally marketed devices identified in this 510(k) summary.
3
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/3/Picture/1 description: The image contains the text "Public Health Service". The text is in a simple, sans-serif font and is horizontally aligned. The text is likely part of a document or sign.
Image /page/3/Picture/2 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized image of an eagle or bird-like figure with three distinct head profiles, suggesting a sense of community or collaboration. The bird is positioned to the right of the text, which is arranged in a circular pattern around the left side of the image. The text reads "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA".
January 18, 2013
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-002
St. Jude Medical, Inc., Neuromodulation Division Terrina Wilder, RAC Senior Regulatory Affairs Specialist 6901 Preston Rd. Plano, TX 75024
Re: K123299
Trade/Device Name: MTS Wide-Spaced Quattrode Percutaneous Leads Regulation Numbers: 21 CFR 882.5880 Regulation Name: Stimulator, Spinal Cord, Implanted for Pain Relief Stimulator, Peripheral Nerve, Implanted for Pain Reliefs Regulatory Class: Class II Product Code: GZB, GZF Dated: October 19, 2012 Received: October 23, 2012
Dear Ms. Terrina Wilder:
We have reviewed your Section 510(k) premarket notification of intent to market the device we nave and have and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate for use surfor to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of The general bonnote proving practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it your device to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean r hat FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical
4
Page 2 - Ms. Terrina Wilder
device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set device-related adverse events) (21 CFR Part 820); and if applicable, the electronic forth in the quality systems (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please 11 you uestle specific advice tor your do need career and offices/ucm115809.htm for go to mtp.//www.lua.gov/rtoout Brical Health's (CDRH's) Office of Compliance. Also, please the Center for Devices and Radional by reference to premarket notification" (21CFR Part note the regulation entined, "Wholenants of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the 1 ou may of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address (000) 050 2611 01 (0 MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours,
Joyce M. Whang
for Victor Krauthamer, Ph.D. Acting Director Division of Neurological and Physical Medicine Devices Office of Device Evaluation Center for Devices and Radiological Health
5
Image /page/5/Picture/0 description: The image shows the logo for St. Jude Medical. The logo consists of a 3x3 grid of squares on the left, followed by the text "St. Jude MEDICAL" in a bold, sans-serif font. Below the text, there is a tagline that reads "MORE CONTROL LESS RISK" in a smaller font.
St. Jude Medica Neuromodulation Division 6901 Praston Road Plano TX 75024 USA Tel 972 309 8000 Fax 972 309 8150
Indications for Use 5.0
510(k) Number (if known):
Device Name:
MTS™ System
Indications for Use:
The Multiprogram Trial Stimulator System is indicated for the treatment of chronic pain of the trunk and f the Multiplogian Than Stilliantial agent or as an adjunct to other modes of therapy used in a multidisciplinary approach.
The Multiprogram Trial Stimulator System is intended to be used with St. Jude Medical Neuromodulation The Maniprogram That Scimal test extensions to deliver targeted paresthesia to single or Division perculuneous that lease and ther intraoperatively or postoperatively for up to a maximum of 30 days.
Prescription Use (Part 21 CFR 801 Subpart D) AND/OR
Over-The-Counter Use (21 CFR 801 Subpart C)
(Please DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Joyce M. Whang
Page 1 of
Division of Neurological and Physical Medicine Devices 510(k) Number: K123299
Page 10 of 30 .
6
Image /page/6/Picture/0 description: The image shows the logo for St. Jude Medical. The logo consists of a grid of nine squares on the left, followed by the text "ST. JUDE MEDICAL" in a serif font. Below the text, in smaller letters, is the phrase "MORE CONTROL LESS RISK".
St. Jude Medical Neuromodulation Division 6901 Preston Road Plano, TX 75024 USA Tel 972 309 8000 Fax 972 309 8150
5.1 Indications for Use
510(k) Number (if known):
Device Name:
Wide-Spaced Quattrode™ Leads
Indications for Use:
The St. Jude Medical Neuromodulation Division neurostimulation systems are indicated for spiral cord rrie 3t. Jude Medical Nedromedation of the trunk and limbs, either as the sole mitigating Stimulution (800) in the vo other modes of therapy used in a multidisciplinary approach.
St. Jude Medical Neuromodulation Division percutaneous leads model numbers 3066, 3161, 3163, 3166, 31. Jude Medical Nedromobilers 3382, 3383, 3341, 3342, 3343, and receiver model number 3408, 5105, Excellsion friodel Numbers 1220 and antenna model numbers 1220 and 1230 are also indicated to stimulate electrically peripheral nerves to relieve severe intractable pain.
Prescription Use (Part 21 CFR 801 Subpart D) AND/OR
Over-The-Counter Use (21 CFR 801 Subpart C)
(Please DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Joyce M. Whang
Page 1 of _
Page 11 of 30
Division of Neurological and Physical Medicine Devices 510(k) Number: K123299